Loading data for VRDN — first visit, this takes a few seconds.
Viridian Therapeutics, Inc. (VRDN)
NasdaqCM: VRDN
· 实时价格 · USD
22.92
-0.04 (-0.17%)
收盘价： Sep 04, 2026, 8:00 PM
22.80
-0.52%
盘后: 7:30 PM
股价、关键数字和最新消息，都在这一页。
Viridian Therapeutics, Inc.（VRDN）股价、分析与数据
暂无数据
| 买价 | 16.97 |
| 市值 | 2.6B |
| 营收（TTM） | 71.1M |
| 净利润（TTM） | -334M |
| 0.96 | |
| -3.4 | |
| n/a | |
| -8.27 | |
| 市净率（TTM） | 4.66 |
| 市销率（TTM） | 36.51 |
| 财报日期 | Nov 5, 2026 |
| 卖价 | 22.94 |
| 成交量 | 759,913 |
| 20日均量 | 1,885,990 |
| 开盘价 | 22.62 |
| 前收盘价 | 22.96 |
| 日内区间 | 22.62 - 23.03 |
| 52周区间 | 13.18 - 34.29 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TS...
公司完整简介财报意外
Viridian Therapeutics 已于 Aug 6, 2026 发布季度财报：
- 营收为 $284K 低于预期 $0, ， 278.67% 同比增长.
- 每股收益为 -1.05 低于预期 -0.02, ， -5.00% 同比下滑.
第 1 页，共 2 页